Lapatinib Resistance Confers Cross-Resistance to Microtubule Inhibitors in ErbB2-Overexpressing Breast Cancer Cells

被引：0
|
作者：
Araki, K. [1 ]
Gallas, M. [1 ]
Liu, X. [1 ]
Jegg, A-M [1 ]
Ward, T. [1 ]
Pegram, M. [1 ]
机构：
[1] Univ Miami, Coral Gables, FL 33124 USA
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-01-05
引用
收藏
页数：1
相关论文
共 50 条
  • [31] MM-111, an ErbB2/ErbB3 bispecific antibody, effectively combines with lapatinib to inhibit growth of ErbB2-overexpressing tumor cells
    Oyama, Shinji K.
    Paragas, Violette
    Adams, Sharlene
    Luus, Lia
    Huhalov, Alexandra
    Kudla, Arthur J.
    Overland, Ryan
    Nielsen, Ulrik B.
    Niyikiza, Clet
    McDonagh, Charlotte F.
    MacBeath, Gavin
    [J]. CANCER RESEARCH, 2011, 71
  • [32] Grb2 downregulation leads to Akt inactivation in heregulin-stimulated and ErbB2-overexpressing breast cancer cells
    Soo-Jeong Lim
    Gabriel Lopez-Berestein
    Mien-Chie Hung
    Ruth Lupu
    Ana M Tari
    [J]. Oncogene, 2000, 19 : 6271 - 6276
  • [33] Grb2 downregulation leads to Akt inactivation in heregulin-stimulated and ErbB2-overexpressing breast cancer cells
    Lim, SJ
    Lopez-Berestein, G
    Hung, MC
    Lupu, R
    Tari, AM
    [J]. ONCOGENE, 2000, 19 (54) : 6271 - 6276
  • [34] Characterization of human breast cancer cells with acquired resistance to the EGFR/ErbB-2 tyrosine kinase inhibitor lapatinib
    De Luca, Antonella
    Faraso, Stefania
    D'Alessio, Amelia
    Gallo, Marianna
    Lamura, Luana
    Maiello, Monica R.
    Normanno, Nicola
    [J]. CANCER RESEARCH, 2011, 71
  • [35] Hypoxia induces lapatinib resistance in ErbB2-positive breast cancer cells via regulation of DUSP2
    Karakashev, Sergey
    [J]. CANCER RESEARCH, 2014, 74 (19)
  • [36] Hypoxia induces lapatinib resistance in ErbB2-positive breast cancer cells via regulation of DUSP2
    Karakashev, Sergey V.
    Mauricio, Reginato J.
    [J]. CANCER RESEARCH, 2013, 73
  • [37] PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer
    T Fujita
    H Doihara
    K Kawasaki
    D Takabatake
    H Takahashi
    K Washio
    K Tsukuda
    Y Ogasawara
    N Shimizu
    [J]. British Journal of Cancer, 2006, 94 : 247 - 252
  • [38] PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer
    Fujita, T
    Doihara, H
    Kawasaki, K
    Takabatake, D
    Takahashi, H
    Washio, K
    Tsukuda, K
    Ogasawara, Y
    Shimizu, N
    [J]. BRITISH JOURNAL OF CANCER, 2006, 94 (02) : 247 - 252
  • [39] Accumulation of Multiple Mutations In Vivo Confers Cross-Resistance to New and Existing Integrase Inhibitors
    Zhang, Wendy W.
    Cheung, Peter K.
    Oliveira, Natalia
    Robbins, Marjorie A.
    Harrigan, P. Richard
    Shahid, Aniqa
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2018, 218 (11): : 1773 - 1776
  • [40] Pharmacologic Inhibition of mTOR Improves Lapatinib Sensitivity in HER2-Overexpressing Breast Cancer Cells with Primary Trastuzumab Resistance
    Gayle, Sylvia S.
    Arnold, Samuel L. M.
    O'Regan, Ruth M.
    Nahta, Rita
    [J]. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2012, 12 (02) : 151 - 162
12345